Navigation Links
Nventa updates progress of cervical dysplasia trial with new HspE7
Date:10/18/2007

e HIV-positive with low-grade CIN.

About HspE7, Lead Product Candidate:

------------------------------------

HspE7 is a novel therapeutic vaccine candidate for the treatment of diseases caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Heat shock proteins (Hsps), also known as stress proteins, are naturally present in the human body and play important roles in the immune system, including transporting substances within cells and activating cells of the immune system.

About Nventa Corporation:

-------------------------

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa, please visit http://www.nventacorp.com.

This press release contains statements which may constitute forward-looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements or information may include financial and other projections as well as statements regarding the Company's future plans, objectives, performance, revenues, growth, profits, operating expenses or the Company's underlying assumptions. The words "may", "would", "could", "will", "likely", "expect," "anticipate," "intend", "plan", "forecast", "project", "estimate" and "believe" or other similar words and phrases may identify forward-looking statements or information. Persons reading this press
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Merge announces sofware updates, upcoming acquisition
2. Tech Digest: Merge eMed product updates; Renaissance Learning 3rd qtr results
3. Solinus updates MailFoundry anti-spam hardware, switching to Linux
4. Wingra Technologies updates data migration software
5. Wisconsin cities make progress on wireless Internet coverage
6. Doyle laments lack of progress on stem cell bill
7. U.S. health system could undermine EHR progress
8. Stem-cell controversies slow progress
9. VC trends, company progress discussed at Mason Wells portfolio meeting
10. Can you keep ahead of progress? An exclusive interview with Rick Smith of iNoc
11. Furious pace of Midwest biotech events marks progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Can economic incentives such as gift cards, ... the public to increase their donations of blood? , ... Business School Assistant Professor Mario Macis says the ... body of recent research that supports their argument, the ... of Science that the World Health Organization and national ...
(Date:5/23/2013)... 23, 2013  Rahal Letterman Lanigan Racing (RLL) and ... stem cell banking and therapeutics, announced today that StemCyte ... Acorn Stairlifts Indy car driven by James ... the IZOD IndyCar 2013 season.   StemCyte, ... support awareness of umbilical cord blood banking and its ...
(Date:5/23/2013)...  Saddleback Memorial Medical Center in Laguna ... on the West Coast to perform a hysterectomy using ... women with a state-of-the-art, minimally invasive approach to gynecological ... , M.D., a highly regarded Orange County ... minimally invasive surgery at Saddleback Memorial, led the surgical ...
(Date:5/23/2013)... May 23, 2013 Z Trim Holdings, Inc. ... to a variety of industries, announced that Chef ... discussion at this year,s National Restaurant Association ("NRA") NRA ... behalf of the Research Chefs Association.  Chef Ryan spoke ... Good, the Bad and the Ugly," joining four other ...
Breaking Biology Technology:Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
... Pipeline Efforts at 27th Annual J.P. Morgan Healthcare Conference ... (Nasdaq: GHDX ) announced today that it ... 18-gene Oncotype DX(R) colon cancer assay. Utilizing more ... the validation study will use prospectively defined endpoints to ...
... Jan. 12 WaferGen Biosystems,Inc. (OTC Bulletin ... gene,expression, genotyping, cell biology and stem cell ... successfully demonstrated the,performance of the company,s SmartChip(TM) ... the platform,s ongoing alpha testing program. ...
... - Trial conducted by Novartis to evaluate safety and ... with ribavirin in patients with genotypes 2 and 3 ... Sciences, Inc. (Nasdaq: HGSI ) today announced ... trial that will evaluate the safety and efficacy of ...
Cached Biology Technology:Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 2Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 3Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 4Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 5WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 2WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 3WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 4WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 5Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 2Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 3Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 4Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 5
(Date:5/24/2013)... and grow by avoiding detection and destruction by the ... to eliminate cancer cells; however, there are many factors ... Regulatory T cells are immune cells that function to ... the Journal of Clinical Investigation , researchers led ... T cells that infiltrate tumors express proteins that can ...
(Date:5/23/2013)... Frontiers in Plant Science , ... gene content and promoter evolution among grasses , ... of stretches of DNA that undergo little change in ... not code for any proteins. Some of these evolutionarily ... to regulate the expression of other genes or the ...
(Date:5/23/2013)... which estrogen suppresses lipid synthesis in the liver, UC ... treating certain liver diseases. , With this finding, ... long-held views in the field. Study results appear in ... Signaling . , "The dogma in the steroid receptor ... located in the nucleus respond to steroid hormones by ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2
... WASHINGTON To reduce the risk of another ... oil spill, a new report from the National Academy ... in offshore drilling should take a "system safety" approach ... of operation -- from ensuring the integrity of wells ...
... reporting development of a first-of-its-kind technology that could help ... involving nerve gas and other chemical agents back to ... ingredients for the agent. A report on the technique, ... attacks, appears in ACS, journal Analytical Chemistry . ...
... Athens, Ga. When you cut an apple and ... lemon juice, an antioxidant, and the process slows down. ... the brain as Alzheimer,s disease sets in. The underlying cause ... with the creation of free radicals that cause oxidative stress. ...
Cached Biology News:Industry, regulators should take 'system safety' approach to offshore drilling in aftermath of Deepwater Horizon accident, says new report 2Industry, regulators should take 'system safety' approach to offshore drilling in aftermath of Deepwater Horizon accident, says new report 3Antioxidant has potential in the Alzheimer's fight, UGA researchers find 2
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
... Anti-Matrix Metalloproteinase-2, Hinge Region By immunoblotting the ... protein. It reacts with free MMP-2 or ... buffered aqueous glycerol solution Solution ... 7.4, containing 50% glycerol and 15 mM ...
human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
... exerts its effects by ... receptor, a disulfide-linked heterotetrameric ... Alpha subunits and two ... the following configuration: Beta-Alpha-Alpha-Beta. ...
Biology Products: